IN2012DN00857A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00857A
IN2012DN00857A IN857DEN2012A IN2012DN00857A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A IN 857DEN2012 A IN857DEN2012 A IN 857DEN2012A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A
Authority
IN
India
Prior art keywords
pth
excellent safety
drug
achievement
inhibiting
Prior art date
Application number
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Masunaga
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of IN2012DN00857A publication Critical patent/IN2012DN00857A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method.
IN857DEN2012 2009-09-09 2010-09-08 IN2012DN00857A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Publications (1)

Publication Number Publication Date
IN2012DN00857A true IN2012DN00857A (en) 2015-07-10

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN857DEN2012 IN2012DN00857A (en) 2009-09-09 2010-09-08

Country Status (17)

Country Link
US (3) US20120252729A1 (en)
EP (3) EP2682124B1 (en)
JP (13) JPWO2011030774A1 (en)
KR (8) KR102335703B1 (en)
CN (2) CN102470164B (en)
AU (1) AU2010293488B2 (en)
BR (1) BR112012003511A2 (en)
CA (1) CA2772656A1 (en)
ES (3) ES2663322T3 (en)
HK (1) HK1168284A1 (en)
IL (1) IL217854A (en)
IN (1) IN2012DN00857A (en)
MX (1) MX335951B (en)
NZ (2) NZ617397A (en)
RU (1) RU2564894C2 (en)
WO (1) WO2011030774A1 (en)
ZA (1) ZA201201720B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339484B (en) * 2009-11-18 2016-05-27 Asahi Kasei Pharma Corp Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis.
JP6235219B2 (en) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 Bone fusion promoter after spinal interbody fusion
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
WO2019059303A1 (en) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability
JP2019060866A (en) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 Method for predicting biokinetics of liquid pharmaceutical composition
JP6577683B2 (en) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 Liquid pharmaceutical composition containing teriparatide having excellent stability
JP7080487B2 (en) 2018-09-26 2022-06-06 東陽建設工機株式会社 Reinforcing bar bending method
CN111447943A (en) 2018-10-29 2020-07-24 旭化成制药株式会社 Method for preventing or treating osteoporosis characterized by administering teriparatide or a salt thereof at a frequency of 2 times per week

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (en) 1987-07-10 1996-06-12 旭化成工業株式会社 Freeze-dried composition of h-PTH (1-34)
JP2662842B2 (en) 1991-12-09 1997-10-15 旭化成工業株式会社 Parathyroid hormone stabilizing composition
JPH0873376A (en) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd Therapeutic agent for osteoporosis
SE9702401D0 (en) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (en) 1998-08-19 2003-12-15 Lilly Co Eli Method for increasing bone hardness and stiffness.
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
MY136546A (en) 2000-06-30 2008-10-31 Asubio Pharma Co Ltd A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
JP5042419B2 (en) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 Bone formation promoter and composition for promoting bone formation
JP4931306B2 (en) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 Pharmaceutical complex that safely promotes bone formation
CA2531136A1 (en) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
EP1741441A4 (en) * 2004-04-26 2010-03-03 Ono Pharmaceutical Co Bone densifying agent characterized by use of cathepsin k inhibitor with pth
MXPA06012980A (en) * 2004-05-10 2007-06-12 Nastech Pharm Co Compositions and methods for enhanced mucosal delivery of parathyroid hormone.
US7799754B2 (en) * 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
JP2006241098A (en) * 2005-03-04 2006-09-14 Univ Kurume Medicine for preventing or treating osteopenia
DE102006043846A1 (en) * 2006-03-14 2007-09-20 Claudia Zours Spinal
US20080039775A1 (en) * 2006-03-15 2008-02-14 Alza Corporation Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia
CN101274961A (en) * 2006-03-30 2008-10-01 天津医科大学 Recombinant human parathyroid hormone related protein
CN101125201A (en) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 Medicine composition for treating osteoporosis or preventing bone fracture caused by osteoporosis and its application
CN101307105B (en) * 2008-04-28 2012-08-29 中国药科大学 Human parathyroid hormone 1-34 peptide analogue capable of expressing in series and being released by synchronousacid hydrolysis, preparation method thereof and use

Also Published As

Publication number Publication date
KR20200115673A (en) 2020-10-07
KR102335703B1 (en) 2021-12-07
EP2682125B1 (en) 2020-11-04
JP2015157854A (en) 2015-09-03
NZ598370A (en) 2014-04-30
JP2017061511A (en) 2017-03-30
EP2476429A1 (en) 2012-07-18
US20120252729A1 (en) 2012-10-04
RU2564894C2 (en) 2015-10-10
JP2017105860A (en) 2017-06-15
NZ617397A (en) 2015-02-27
KR20120067336A (en) 2012-06-25
JP2016130261A (en) 2016-07-21
IL217854A (en) 2016-08-31
CN102470164A (en) 2012-05-23
JP6043008B2 (en) 2016-12-14
WO2011030774A1 (en) 2011-03-17
JP2018024710A (en) 2018-02-15
EP2682124A1 (en) 2014-01-08
KR20140130754A (en) 2014-11-11
MX2012002681A (en) 2012-04-19
JP6522715B2 (en) 2019-05-29
JP6275900B2 (en) 2018-02-07
CA2772656A1 (en) 2011-03-17
EP2682125A1 (en) 2014-01-08
KR102424644B1 (en) 2022-07-25
MX335951B (en) 2016-01-04
ES2663322T3 (en) 2018-04-12
IL217854A0 (en) 2012-03-29
AU2010293488A1 (en) 2012-03-29
JP2015147813A (en) 2015-08-20
ZA201201720B (en) 2012-11-28
JP2017105862A (en) 2017-06-15
JP6198346B2 (en) 2017-09-20
RU2012108635A (en) 2013-10-20
KR20170089018A (en) 2017-08-02
EP2476429B1 (en) 2018-03-07
JP6274634B2 (en) 2018-02-07
KR20170089017A (en) 2017-08-02
ES2843649T3 (en) 2021-07-20
US20140249084A1 (en) 2014-09-04
KR20190095552A (en) 2019-08-14
JP6150846B2 (en) 2017-06-21
JP2017105861A (en) 2017-06-15
JPWO2011030774A1 (en) 2013-02-07
AU2010293488B2 (en) 2014-11-27
ES2662018T3 (en) 2018-04-05
US20140357560A1 (en) 2014-12-04
JP2017105859A (en) 2017-06-15
JP2017105858A (en) 2017-06-15
JP6301524B2 (en) 2018-03-28
EP2682124B1 (en) 2018-02-28
HK1168284A1 (en) 2012-12-28
BR112012003511A2 (en) 2019-09-24
EP2476429A4 (en) 2013-02-27
CN102470164B (en) 2014-04-09
JP2019023234A (en) 2019-02-14
KR20210040171A (en) 2021-04-12
KR20150021590A (en) 2015-03-02
CN103893746A (en) 2014-07-02
JP2017105863A (en) 2017-06-15

Similar Documents

Publication Publication Date Title
IN2012DN00857A (en)
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MY168791A (en) Carbamate compounds and of making and using same
MX363243B (en) Compositions and methods for treating cancer.
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2013013809A (en) Expandable devices coated with a paclitaxel composition.
IN2015DN03219A (en)
MX338554B (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain.
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MY164864A (en) Indenone derivative and pharmaceutical composition comprising same
MX369117B (en) Selective ep4 receptor agonistic substance for treatment of cancer.
MX2013008074A (en) Combination.
SA113340494B1 (en) Composition for treating metabolic disorders
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
IN2014DN09779A (en)
MX2012003892A (en) Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis.
WO2011089531A3 (en) Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture
MX2014015096A (en) Crustacean feed.
MX2015012666A (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor.
MX2014013491A (en) Methods of maintaining, treating or improving cognitive function.
WO2011136585A3 (en) Composition for treating bone disease comprising a glyceollin as an active ingredient
UA56460U (en) Method for treating traumatic injuries of peripheral nerve
UA53407U (en) Method for preventive maintenance and treatmens пepehaшиbahиe pregnancy
MX341960B (en) A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease.